From: Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
 | Before propensity-score overlap weighting | After propensity-score overlap weighting | ||||
---|---|---|---|---|---|---|
 | BNT162b2 | ChAdOx1 | Standardized difference | BNT162b2 | ChAdOx1 | Standardized difference |
Number | 536,371 | 774,704 | Â | 163,716 | 163,716 | Â |
Demographics | ||||||
 Age, mean (SD), y | 46.37 (19.13) | 57.82 (14.82) | 0.669 | 58.32 (15.77) | 58.32 (16.75) | <0.001 |
 Race (%) |  |  | 0.075 |  |  | <0.001 |
  White | 42.7 | 46 |  | 45 | 45 |  |
  Other | 3.4 | 2.6 |  | 2.8 | 2.8 |  |
  Missing | 53.9 | 51.3 |  | 52.2 | 52.2 |  |
 Socioeconomic deprivation index score (%)a |  |  | 0.052 |  |  | <0.001 |
  1 | 15.5 | 15.8 |  | 16.7 | 16.7 |  |
  2 | 18.5 | 19.7 |  | 19.8 | 19.8 |  |
  3 | 19.7 | 20.1 |  | 19.8 | 19.8 |  |
  4 | 18.6 | 18.6 |  | 17.7 | 17.7 |  |
  5 | 15.5 | 14.9 |  | 14.2 | 14.2 |  |
  Missing | 12.2 | 10.9 |  | 11.9 | 11.9 |  |
 Female (%) | 52.9 | 50.3 | 0.052 | 52.2 | 52.2 | <0.001 |
BMI, mean (SD), kg/m2 | 27.44 (5.87) | 28.45 (6.30) | 0.165 | 27.98 (5.80) | 28.07 (6.00) | 0.015 |
Region | Â | Â | 0.105 | Â | Â | <0.001 |
 England | 14.8 | 13.6 |  | 15.1 | 15.1 |  |
 Northern Ireland | 15.3 | 12.3 |  | 17.6 | 17.6 |  |
 Scotland | 39.1 | 42.8 |  | 38.1 | 38.1 |  |
 Wales | 30.8 | 31.4 |  | 29.2 | 29.2 |  |
Influenza vaccination (%)b | 31.8 | 45 | 0.272 | 49.1 | 49.1 | <0.001 |
Lifestyle factors | ||||||
 Drinking (%) |  |  | 0.037 |  |  | <0.001 |
  None | 19.1 | 18.1 |  | 18.2 | 18.2 |  |
  Past | 2.9 | 3.4 |  | 3.5 | 3.5 |  |
  Current | 77.9 | 78.5 |  | 78.3 | 78.3 |  |
 Smoking (%) |  |  | 0.134 |  |  | <0.001 |
  None | 62 | 55.8 |  | 56.9 | 56.9 |  |
  Past | 21.7 | 26.8 |  | 27.5 | 27.5 |  |
  Current | 16.2 | 17.4 |  | 15.6 | 15.6 |  |
Comorbidity (%) | ||||||
 Hypertension | 18.2 | 28.7 | 0.249 | 30.5 | 30.5 | <0.001 |
 Diabetes | 8.9 | 14 | 0.162 | 14.1 | 14.1 | <0.001 |
 Chronic kidney disease | 3.0 | 5.0 | 0.102 | 5.5 | 5.5 | <0.001 |
 Pneumonia or infection | 5.4 | 6.8 | 0.060 | 6.7 | 6.7 | <0.001 |
 Chronic obstructive pulmonary disease | 2.3 | 4.4 | 0.112 | 4.6 | 4.6 | <0.001 |
 Influenza | 3.1 | 3.6 | 0.030 | 3.6 | 3.6 | <0.001 |
 Cancer | 6.3 | 9.2 | 0.106 | 10.4 | 10.4 | <0.001 |
 Venous thrombosis | 1.5 | 2.6 | 0.079 | 2.5 | 2.5 | <0.001 |
 Atrial fibrillation | 2.2 | 3.8 | 0.095 | 4.1 | 4.1 | <0.001 |
 Ischemic heart disease | 4 | 6.7 | 0.120 | 7.3 | 7.3 | <0.001 |
 Myocardial infarction | 1.8 | 3.2 | 0.088 | 3.3 | 3.3 | <0.001 |
 Congestive heart failure | 1.1 | 2.0 | 0.075 | 2.0 | 2.0 | <0.001 |
 Stroke | 1.4 | 2.6 | 0.085 | 2.6 | 2.6 | <0.001 |
 Trauma | 0.9 | 1.1 | 0.025 | 1.0 | 1.0 | <0.001 |
 Fracture | 31.2 | 33.3 | 0.044 | 32.6 | 32.6 | <0.001 |
 Liver disease | 2.2 | 3.4 | 0.075 | 3.4 | 3.4 | <0.001 |
 Fall | 5.8 | 7.8 | 0.079 | 8.0 | 8.0 | <0.001 |
 Dementia | 0.6 | 1.1 | 0.053 | 1.1 | 1.1 | <0.001 |
 Depression | 12.4 | 15.2 | 0.083 | 14.4 | 14.4 | <0.001 |
Medication (%)b | ||||||
 Antihypertensive | 22.1 | 33 | 0.247 | 34.8 | 34.8 | <0.001 |
 Antidiabetic | 4.5 | 7.9 | 0.142 | 7.6 | 7.6 | <0.001 |
 Statin | 15 | 23.2 | 0.212 | 25.9 | 25.9 | <0.001 |
 Loop diuretics | 2.0 | 3.9 | 0.117 | 3.8 | 3.8 | <0.001 |
 Thiazide diuretics | 3.6 | 5.5 | 0.093 | 6.2 | 6.2 | <0.001 |
 Glucocorticoids | 3.3 | 5 | 0.084 | 5.2 | 5.2 | <0.001 |
 NSAIDs | 16.1 | 21.4 | 0.136 | 21.2 | 21.2 | <0.001 |
 Opioids | 5.0 | 8.1 | 0.127 | 7.6 | 7.6 | <0.001 |
 PPIs | 20.1 | 27.9 | 0.182 | 28.5 | 28.5 | <0.001 |
 DMARDs | 1.1 | 1.7 | 0.051 | 1.9 | 1.9 | <0.001 |
Healthcare utilization, mean (SD)b | ||||||
 Hospitalizationsb | 0.19 (0.70) | 0.24 (0.86) | 0.057 | 0.24 (0.82) | 0.24 (0.80) | <0.001 |
 General practice visitsb | 1.69 (3.13) | 2.13 (3.95) | 0.123 | 2.13 (3.87) | 2.13 (3.53) | <0.001 |
 Specialist referralsb | 0.21 (0.62) | 0.23 (0.66) | 0.026 | 0.24 (0.67) | 0.24 (0.69) | <0.001 |